Plain-English translation of NCT04716257 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a real-world study that follows women who have been diagnosed with colorectal cancer that has spread to their ovaries. Researchers will collect information about the different treatment approaches doctors use and how patients respond to those treatments. The goal is to understand which strategies work best for this specific type of cancer spread.
When colorectal cancer spreads to the ovaries, it can be particularly challenging to treat. This study exists to learn from actual patient experiences and medical records so doctors can better understand which treatment approaches lead to the best outcomes for women facing this diagnosis.
You likely qualify if…
You likely don't qualify if…
You would not receive a new medication or undergo special procedures for this study. Instead, researchers would collect your existing medical records and imaging scans to track what treatments you receive in your normal cancer care and how well those treatments work for you over time. Your doctors would continue your regular care, and the study team would simply document your treatment choices and outcomes.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China
Sponsor
West China Hospital
Collaborators
Sun Yat-sen University, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute
Enrollment target
~400 participants
Started
January 2021
Primary completion
September 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Sex
Female only
Last updated on clinicaltrials.gov in August 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Meng Qiu, M.D.
West China Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.